Core Points - Algernon Health Inc. has closed the second tranche of its non-brokered private placement, raising gross proceeds of CAD $210,000 from the sale of 3,000,000 units at an issue price of CAD $0.07 per unit [2][3] - The funds raised will be utilized to advance the company's Alzheimer's Disease program, including the opening of its first U.S. Alzheimer's Disease clinic, as well as for general administrative expenses and working capital [3] - The securities issued are subject to a statutory hold period of four months plus a day from the date of issuance in accordance with Canadian securities legislation [4] Company Overview - Algernon Health is a Canadian healthcare company focused on providing brain-optimized PET scanning services for early-stage detection of Alzheimer's Disease and other neurological conditions [6] - The company has established a private subsidiary, Algernon USA LLC, to oversee its U.S. neuroimaging operations [6]

Core Viewpoint - Algernon Health Inc. is conducting a non-brokered private placement to raise gross proceeds of $500,000 through the issuance of units priced at $0.07 each, aimed at advancing its Alzheimer's Disease program and other operational needs [1][5]. Group 1: Offering Details - The offering consists of units, each comprising one Class A common share and one-half common share purchase warrant, with a full warrant allowing the purchase of one common share at an exercise price of $0.15 for 12 months [2]. - The exercise price of the common warrants will increase to $0.25 after the first anniversary and to $0.50 after the second anniversary of the issuance date [2][3]. - The offering is expected to close in tranches by November 30, 2025, with potential cash finder's fees of up to 8% of the proceeds [4]. Group 2: Use of Proceeds - Proceeds from the offering will be utilized to advance the company's Alzheimer's Disease program, cover general and administrative expenses, and for working capital purposes [5]. Group 3: Share Structure and Securities - The company has converted 1,268,334 subscription receipts into Series 1 preferred shares and issued additional preferred shares and warrants related to previous placements and acquisitions [7]. - The Series 1 preferred shares carry a 10% annual dividend and are convertible into ten Class A common shares, with voting rights [9]. Group 4: Company Overview - Algernon Health focuses on brain-specific PET scanning services for early-stage detection of Alzheimer's and other neurological conditions, and is advancing a psychedelic program for recovery from stroke and traumatic brain injury [10].